7DIA image
Entry Detail
PDB ID:
7DIA
Title:
Falcilysin in complex with mefloquine
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-11-18
Release Date:
2021-12-01
Method Details:
Experimental Method:
Resolution:
1.55 Å
R-Value Free:
0.19
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Falcilysin
Chain IDs:A
Chain Length:1158
Number of Molecules:1
Biological Source:Plasmodium falciparum 3D7
Primary Citation
Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development.
Cell Chem Biol 31 743 759.e8 (2024)
PMID: 38593807 DOI: 10.1016/j.chembiol.2024.03.002

Abstact

Identification of new druggable protein targets remains the key challenge in the current antimalarial development efforts. Here we used mass-spectrometry-based cellular thermal shift assay (MS-CETSA) to identify potential targets of several antimalarials and drug candidates. We found that falcilysin (FLN) is a common binding partner for several drug candidates such as MK-4815, MMV000848, and MMV665806 but also interacts with quinoline drugs such as chloroquine and mefloquine. Enzymatic assays showed that these compounds can inhibit FLN proteolytic activity. Their interaction with FLN was explored systematically by isothermal titration calorimetry and X-ray crystallography, revealing a shared hydrophobic pocket in the catalytic chamber of the enzyme. Characterization of transgenic cell lines with lowered FLN expression demonstrated statistically significant increases in susceptibility toward MK-4815, MMV000848, and several quinolines. Importantly, the hydrophobic pocket of FLN appears amenable to inhibition and the structures reported here can guide the development of novel drugs against malaria.

Legend

Protein

Chemical

Disease

Primary Citation of related structures